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Abstract: This study investigated the prophylactic effects of orally administered surface-deacetylated
chitin nanofibers (SDACNFs) and chitosan against 5-fluorouracil (5-FU)-induced intestinal mucositis,
which is a common side effect of 5-FU chemotherapy. SDACNFs and chitosan abolished histological
abnormalities associated with intestinal mucositis and suppressed hypoproliferation and apoptosis
of intestinal crypt cells. These results indicate that SDACNF and chitosan are useful agents for
preventing mucositis induced by anti-cancer drugs.
Keywords: surface deacetylated chitin nanofiber; chitosan; mucositis; 5-fluorouracil; apoptosis
1. Introduction
Intestinal mucositis is a common side effect of anti-cancer drugs [1]. The antimetabolite anticancer
agent 5-fluorouracil (5-FU) is widely used to treat malignancies as it improves tumor-free status and
survival rates [2]. However, 50%–80% of patients treated with 5-FU exhibit mucositis as a side effect,
with symptoms including severe diarrhea [3–5]. This often necessitates a reduction in drug dosage or
even discontinuation of the treatment, which limits the success of cancer chemotherapy.
Chitosan is a linear polysaccharide of the chitin family derived from partial deacetylation
of chitin [6]. It is a copolymer comprising (1 → 4)-2-acetamido-2-deoxy-β-D-glucan (N-acetyl-D-
glucosamine) and (1→ 4)-2-amino-2-deoxy-β-D-glucan (D-glucosamine) units distributed throughout
the biopolymer chain either randomly or as a block, depending on the specific method of
deacetylation [7]. Chitosan has diverse pharmaceutical and biomedical applications due to its
availability, non-toxicity, biocompatibility, biodegradability, and broad range of functionalities [7].
In fact, chitosan was shown to prevent gastrointestinal toxicity induced by 5-FU or doxorubicin without
interfering with the anti-cancer effects [8,9].
Simple methods for preparing chitin nanofibers have recently been established [10–12]. In
surface-deacetylated chitin nanofibers (SDACNFs), the nanofiber surface was transformed into chitosan
by deacetylation while the core was maintained as a chitin crystal [13]. Owing to cationic electrostatic
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repulsive forces, the deacetylated chitin readily disintegrated and the SDACNFs were homogeneously
dispersed in water. We have reported that SDACNFs have various biological activities, including
effects on obesity and hypercholesterolemia by oral administration [14,15] and on wound healing by
topical application [16,17]. In this study, we investigated the prophylactic effects of orally administered
SDACNFs against 5-FU-induced intestinal mucositis.
2. Results and Discussion
2.1. SDACNFs Suppress the Effects of 5-FU-Induced Intestinal Mucositis
Low-magnification images and scanning electron micrographs of SDACNF and chitosan are
shown in Figure 1. Chitosan was dissolved in 0.5% acetic acid, whereas SDACNF was a gel that formed
a nanofiber network. The study design is shown schematically in Figure 2. There were no differences
in small intestine length and weight-to-length ratio among control, SDACNF, chitosan, and cellulose
nanofiber (CLNF) groups (data not shown). In the latter two groups, mucosal architecture, ulceration
of the mucosa, reduction in villus height, and inflammatory cell infiltration (MI) were observed by
hematoxylin and eosin (H&E) staining (Figure 3). However, these were not detected in the chitosan
and SDACNF groups.
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(3.0 ± 0.3 cells/field) groups than in the control (6.1 ± 0.3 cells/field) and CLNF (5.5 ± 0.4 cells/field)
groups (each p < 0.01, Figures 4 and 5).
Table 1. Histological score. Data represent mean ± S.E. Each H&E section was scored according
to mucosal architecture (MA; general structure, cell distribution, mucosal and submucosal aspects),
ulceration (MU), inflammation (MI), and villus height (VI). The score ranged from 0 (no alteration) to
3 (severe alteration). * p < 0.05 vs. control group; † p < 0.05. NT: No treatment; Control: control group;
SDACNF: surface deacetylated chitin nanofiber group; Chitosan: chitosan group; CLNF: cellulose
nanofiber group.
NT Control SDACNF Chitosan CLNF
MA 0.0 ± 0.0 1.8 ± 0.6 0.8 ± 0.6 *,† 1.1 ± 0.6 1.8 ± 0.8
MU 0.0 ± 0.0 1.8 ± 0.6 0.8 ± 0.6 *,† 1.2 ± 0.6 1.8 ± 0.6
MI 0.0 ± 0.0 1.9 ± 0.5 0.7 ± 0.5 *,† 0.9 ± 0.5 * 1.5 ± 0.5
VI 0.0 ± 0.0 1.6 ± 0.7 0.8 ± 0.5 *,† 1.1 ± 0.7 1.8 ± 0.7
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Neutrophils are the first cells that arrive at the site of inflammation, and they induce an increase
in myeloperoxidase (MPO) activity in the first hours after 5-FU administration [18,19]. Intestinal
mucositis is characterized histologically by a shortening of intestinal villi and disruption of intestinal
crypts [3–5]. Control mice in the present study exh bited intestin l ucositis; in contrast, this was
suppressed i the SDACNF and chi san groups, indicating that oral adm nistration of SDACNF and
chitosan inhibits 5-FU-induced histological damage associated with mucositis.
2.2. SDACNF Prevents Apoptosis of Intestinal Crypt Cells Induced by 5-FU
The results of Ki-67 immunohistochemistry revealed greater numbers of Ki-67-positive cells
in the crypt in the SDACNF (83.6 ± 3.4 cells/field) and chitosan (71.5 ± 3.3 cells/field) groups
than in the control (43.5 ± 2.1 cells/field) and CLNF (47.3 ± 3.7 cells/field) groups (p < 0.01 each)
(Figures 6 and 7). On the other hand, there were fewer caspase-3-positive cells in the SDACNF
(1.0 ± 0.2 cells/field), chitosan (2.0 ± 0.4 cells/field), and CLNF (2.4 ± 0.4 cells/field) groups than
in the control (4.0 ± 0.3 cells/field) group (SDACNF vs. control and chitosan vs. control, p < 0.01;
and CLNF vs. control, p < 0.05) (Figures 8 and 9). This was consistent with the results of the
terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay, which showed fewer
TUNEL-positive cells in the SDACNF (4.8 ± 0.5 cells/field) and chitosan (4.9 ± 0.4 cells/field) groups
than in control (8.3 ± 0.6 cells/field) mice (p < 0.05 each) (Figures 10 and 11).
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Figure 6. Immunohistochemical analysis of Ki-67 expression. Images were obtained from one of three
mice per group. Black arrows indicate Ki-67-positive cells. High magnification images are shown. Bar:
50 µm. NT: No treatment; Control: control group; SDACNF: surface deacetylated chitin nanofiber
group; Chitosan: chitosan group; CLNF: cellulose nanofiber group.
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Although the pathogenic mechanism of intestinal mucositis induced by anti-cancer drugs is not
well understood, it is thought to be a consequence of various processes such as apoptosis and abnormal
inflammation in the intestinal mucosa as well hypoproliferation of intestinal crypt cells [20–22]. Ki-67 is
a marker of proliferating cells that is expressed during all active phases of the cell cycle [23]. Our results
indicate that oral administration of SDACNF and chitosan suppresses the crypt cell hypoproliferation
induced by 5-FU.
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Apoptosis is an important consequence of intestinal mucositis induced by anti-cancer drugs such
as 5-FU [24–27]; indeed, we observed an increase in the number of TUNEL- and caspase-3-positive
apoptotic cells in the intestinal crypt of control mice, which was abolished in the SDACNF and chitosan
groups. Caspase-3 is the main downstream effector in apoptosis [28,29], whose activity was shown to be
increased during intestinal cell apoptosis induced by chemotherapy, including 5-FU treatment [30–32].
Our results indicate that oral administration of SDACNF and chitosan suppressed apoptosis in the
intestinal crypt by inhibiting caspase-3 activity. Although the suppression of apoptosis by chitosan
has been previously demonstrated [33], ours is the first report describing the anti-apoptotic effects of
orally administered chitosan in intestinal mucositis. The effectiveness of chitosan-derived gel has been
previously described [34]. However, its mechanism of action is unknown. We have demonstrated that
SDACNFs have similar bioactivity [14,15], and the results of the present study indicate that SDACNFs
are equally or more effective than chitosan in preventing intestinal mucositis. However, the mode of
absorption and metabolites of SDACNFs remain unknown and require clarification in future studies.
3. Materials and Methods
3.1. Animals and Regents
Female C57BL/6 mice (5 weeks old) were purchased from CLEA Japan (Osaka, Japan) and
maintained under standard conditions in a room with constant temperature (22 ± 2 ◦C) and humidity
(50% ± 5%) on a 12:12-h light/dark cycle (lights on, 7:00–19:00 h). Mice had free access to food (CE-2;
CLEA Japan) and tap water during the experimental period. The animal procedures in this study
were approved by the Animal Research Committee of Tottori University (15-T-2, from 1 April 2015 to
31 March 2016).
Chitin (Chitin TC-L) and chitosan (Chitosan FH-80) powder from crab shell were purchased from
Koyo Chemical Co. (Tokyo, Japan). CLNF was purchased from Sugino Machine Co. (BiNFi-s cellulose,
WMa-10002; Sugino Macine Limited, Uodu, Japan). Samples were used at concentrations of 1.0 wt %
in 0.5 wt % aqueous acetic acid.
3.2. Preparation of SDACNFs
SDACNFs were prepared as previously described [13], with some modifications. Chitin
powder (45.0 g) was treated with 20% (w/w) NaOH (1.5 L) for 6 h under reflux and an argon
atmosphere. After deacetylation, the supernatant was removed by decantation, and the precipitate was
thoroughly washed with distilled water and 0.5 wt % aqueous acetic acid by centrifugation to remove
water-soluble products of NaOH, sodium acetate, and alkaline hydrolyzed chitin. For mechanical
disintegration, deacetylated chitin was dispersed in 4.0 L of aqueous acetic acid. The sample was
passed twice through a grinder (MKCA6-3; Masuko Sangyo Co., Kawaguchi, Japan) at 1500 rpm. The
concentration, yield, and degree of deacetylation of surface-deacetylated chitin NFs were 1.3%, 74%,
and 20 wt %, respectively.
3.3. Study Design
Mice were randomized into five groups: untreated controls administered tap water without
5-FU injection; controls administered tap water with 5-FU injection; the SDACNF group administered
SDACNF with 5-FU injection; the chitosan group administered chitosan with 5-FU injection; and the
CLNF group administered CLNF with 5-FU injection. Intragastric administration of tap water or
samples (0.2 mL/head) was carried out from day 0 to day 10 via a catheter. Intestinal mucositis was
induced via single daily intraperitoneal injection of 50 mg/kg 5-FU (Kyowa Hakko Kirin Co., Tokyo,
Japan) over the course of 4 days (days 7–10) after 2 h of oral administration of tap water or sample.
Animals were sacrificed under deep anesthesia 24 h after final 5-FU injection (day 11); the small
intestine (duodenum, jejunum, and ileum) was removed and the length and weight were measured.
The jejunum was immersed overnight in 10% neutralized formalin for histological study.
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3.4. Histological Analysis
Thin sections (4 µm) were cut from each sample for H&E staining and histological analysis.
Each section was examined by microscopy, and histological scoring was carried out as previously
described [19] based on alterations in the mucosal architecture (general structure, cell distribution,
mucosal and submucosal aspects), ulceration, villus height, and inflammatory cell infiltration. The
score ranged from 0 (no alteration) to 3 (severe alteration). Results are presented as the sum of scores
obtained for each parameter. Scoring was based on 10 randomly selected fields at 100× magnification
in three mice per group; mean scores for 30 fields yielded the histological score for each group.
3.5. Ki-67 Immunohistochemistry
Ki-67 immunohistochemistry was carried out according to our previous methods [35]. Tissue
sections (4 µm) were placed on glass slides and deparaffinized, washed with ethanol and water, and
immersed in phosphate-buffered saline (PBS). The sections were autoclaved in 0.01 M citrate buffer
(pH 6.0) for 15 min at 121 ◦C, then washed with PBS and incubated for 30 min at room temperature
with rabbit polyclonal anti-Ki-67 antibody (1:50, E0468; Dako, Glostrup, Denmark). After washes with
PBS, the sections were incubated for 30 min at room temperature with rat anti-IgG (1:100, sc-372; Vector
Laboratories, Burlingame, CA, USA), washed with PBS, stained for 30 min using the Vectastain ABC
kit (PK-4000; Vector Laboratories), then counterstained with HistoGreen (Nichirei Bioscience, Osaka,
Japan) followed by nuclear Fast Red. The number of Ki-67-positive cells in crypts was counted under
the microscope in 10 randomly selected high-power fields (200×magnification) per cross section. The
jejunum of three mice per group were analyzed. The mean number of Ki-67-positive cells in 30 fields
was determined for each group.
3.6. Caspase-3 Immunohistochemistry
Tissue sections (4 µm) were placed on glass slides and deparaffinized, washed with ethanol and
water, and immersed in PBS. The sections were autoclaved in 0.01 M citrate buffer (pH 6.0) for 10 min
at 121 ◦C, washed with PBS and incubated with 0.3% H2O2 to quench intrinsic peroxidase activity.
This was followed by incubation with anti-cleaved caspase-3 (Asp175) antibody (1:400, 9961S; Cell
Signaling Technology, Danvers, MA, USA) for 60 min at room temperature. After washes with PBS,
sections were incubated with Envision (anti-rabbit, K4003; Dako) for 30 min at room temperature.
The slides were washed with PBS, and immunoreactivity was visualized with a diaminobenzidine kit
(S2022; Dako). The number of caspase-3-positive cells in the crypt was counted as described above for
Ki-67 immunohistochemistry.
3.7. TUNEL Assay
The TUNEL assay was carried out as previously described [36]. Tissue sections (3 µm) on glass
slides were deparaffinized, washed with ethanol and water, and immersed in distilled water. TUNEL
staining was performed using the In Situ Apoptosis Detection kit (Takara Bio, Otsu, Japan) according
to the manufacturer’s instructions. The number of TUNEL-positive cells in the crypts was counted as
described above for Ki-67 immunohistochemistry.
3.8. MPO Staining
MPO staining was performed according to standard procedures [37]. The number of MPO-positive
cells in the crypt was counted as described above for Ki-67 immunohistochemistry.
3.9. Statistical Analysis
Data are expressed as the mean ± standard deviation. Statistical analyses were performed using
the Steel–Dwas test. A p-value < 0.05 was considered statistically significant.
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4. Conclusions
In conclusion, oral administration of SDACNF and chitosan suppressed mucosal inflammation
and shortening of intestinal crypts as well as crypt cell apoptosis and hypoproliferation caused by
5-FU treatment. These results indicate that SDACNF and chitosan are useful agents for preventing
mucositis induced by anti-cancer drugs.
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